Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. - Wikidata - awgldk - TriplyDB

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

http://www.wikidata.org/entity/Q33813146

about

Intelligent design: combination therapy with oncolytic viruses Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Herpes simplex virus oncolytic therapy for pediatric malignancies Impact of tumor microenvironment on oncolytic viral therapy Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children.Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs Regional liver therapy using oncolytic virus to target hepatic colorectal metastases.HSV Recombinant Vectors for Gene Therapy.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Progress of oncolytic viruses in sarcomas.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Oncolytic virus therapy for cancer.OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors.BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma.Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

P2860

Q24628227-53A04EC2-65C1-4115-830C-4F63A8FFDBCE Q26863779-CF7FC80F-39D0-452B-BE3A-94B391ABE553 Q33713824-75753469-F355-4282-A094-E398CEF03C92 Q33895533-74E11C65-8700-4965-BDB1-8CB443FE4B0E Q33903856-93DFCA35-1A34-457F-BA55-1B5487B1932F Q33927165-68F97C1D-874B-4DB6-AEDE-1FB16C8ED36D Q33976318-AD427914-FFBF-4A47-8AE9-518C1D49C58D Q33995471-2ECEDA13-3316-4BDE-9184-0FFA6E7C7FC2 Q34046125-37132B80-637D-4940-9262-C0B210F3D914 Q34343768-D07BEF4F-E5E3-4581-9A90-D82BB3678899 Q34556927-67D32642-2854-4A4E-BBD4-0301C907F9D8 Q35591421-F4AA8FD1-6250-4149-9ABC-16D6A6863FB5 Q35699072-F09EB41F-27A0-47CE-AD4B-5CA17C2DBBDE Q35823934-EC3347B1-5703-4C2F-BBE1-78D43499339B Q35876172-4922CC73-5C20-450E-947C-8D17D37873D8 Q36109700-5B3F40FD-EE37-4EED-B89E-64BDD79CA513 Q36109704-AB79C14B-E42A-4EAE-A2C5-B1453A86C250 Q36658280-10555967-136A-4DB3-8093-C7E1AA4B5B61 Q36664245-831E4496-3D12-43C8-813B-3DD191E96E99 Q37031896-66F04071-24FB-41A6-A380-85B4F73F7A62 Q37759934-6135DDF9-9C81-48CC-8521-531DD05E0F73 Q37787777-2F0EB5DC-1237-457B-9A5F-22F3C7B0657F Q37899223-0FFAD372-C4E2-463A-8F0F-2DED052EF8FE Q37899230-8E30DD90-3627-4654-8A6F-BCCDFB2A1279 Q37933439-F1CA00C7-4AC4-4934-BDE9-E9B3F3559E00 Q37982449-5EA3BF4D-36DC-4E5D-83B0-3CF7C9B64C61 Q38237657-D934CB21-30AD-4DF2-A0B2-DAAF9618B671 Q38924529-E3926B1E-0CD7-488C-A602-0A987F92630A Q39866378-B70F3A38-A466-4F1D-8368-98A3E15FE45A Q40145892-D8F0EA6E-485D-423E-8335-FFAFD8D73A30 Q40449206-10D8F8DE-292D-4925-9739-7408E442320E Q41919532-E58FE46B-3E37-4149-848C-E853DF18806B Q42373489-1308103E-FAF8-4610-9ECB-287C9694CF61 Q42937380-E6B8DE92-F59F-4857-A09B-46B48BB87C0A

P2860

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

http://www.wikidata.org/entity/Q33813146

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Efficacy and safety of the onc ...... ombined with cyclophosphamide.

@ast

Efficacy and safety of the onc ...... ombined with cyclophosphamide.

@en

type

label

Efficacy and safety of the onc ...... ombined with cyclophosphamide.

@ast

Efficacy and safety of the onc ...... ombined with cyclophosphamide.

@en

prefLabel

Efficacy and safety of the onc ...... ombined with cyclophosphamide.

@ast

Efficacy and safety of the onc ...... ombined with cyclophosphamide.

@en

P1433

Q33813146-9715E8E1-F245-441A-8734-D471B20288EB

P1476

Q33813146-47AE0C9E-24D6-42D6-A82B-D7BF9D57B2DA

P2093

Q33813146-0024379E-31D9-4F73-9276-BCF211B552C5

Q33813146-0B0E51BF-686F-4A8E-96A3-DFC6485DBD26

Q33813146-26FA8B60-4CE9-4D10-8B77-DC1C76D2E533

Q33813146-2AA35EEF-F495-42A3-BB63-ACD21E2F518B

Q33813146-52B3F769-111E-4422-A89C-6B744465DD75

Q33813146-6D2EECD3-AA9F-4D41-A005-842CA9088799

Q33813146-CF283542-E5B2-476E-AC52-DE6D419F8BEE

Q33813146-DA120E1F-E2D4-40C8-9C11-AF025A10021E

Q33813146-F006A004-F1FD-482B-8DDC-AD590A2E91AC

P2860

Q33813146-03098BF1-96AE-44A8-8F0C-968AFF3AC180

Q33813146-05F6AEFF-2CCE-468D-8282-24E1E56EF669

Q33813146-14333141-4BA1-497B-9D7B-F4BD691B05EE

Q33813146-18F1F747-F0E4-4104-8235-03F2A920FC1C

Q33813146-1F484251-4949-4420-986D-DEA495E36F76

Q33813146-25AF0086-0AD4-4D35-A6D4-6B0BC8021FA0

Q33813146-2EFB8750-6E8E-48BC-8D7A-4C90CD98B386

Q33813146-47677F48-A235-46FA-998D-197112354FCE

Q33813146-47BD79B3-E0EE-48EE-9B41-D6CA23576CA7

Q33813146-4A95BCB6-F287-498B-8D78-ED0D72BF481B

P304

Q33813146-BD28442E-8342-4BF3-8729-2CAD7BF00C2A

P31

Q33813146-53FC236F-3CC0-41C0-9DDF-A88CE7FD856B

P356

Q33813146-C1306E89-A795-4649-898B-4EEC2A084C22

P433

Q33813146-31E1718C-97E0-48DD-A4AA-C2619863B237

P478

Q33813146-1537FBDD-541A-40DE-BF3D-E908E6F45E2F

P577

Q33813146-DEAAA2DD-F839-47D5-B846-293409243293

P5875

Q33813146-DDAFA1C9-FBCC-403E-B967-74A95E291743

P698

Q33813146-C868780C-F5A7-47E2-A7DF-36F58DC937CF

P921

Q33813146-64973406-0BA3-44A9-82FF-EB1DE6AEB09C

P932

Q33813146-D5A9D5BE-F278-4F71-9369-B1E4B12B2247

P356

P1433

Molecular Therapy

P1476

Efficacy and safety of the onc ...... ombined with cyclophosphamide.

@en

P2093

E Antonio Chiocca

http://www.w3.org/2001/XMLSchema#string

Greg Stroup

http://www.w3.org/2001/XMLSchema#string

Hirokazu Kambara

http://www.w3.org/2001/XMLSchema#string

Margaret H Collins

http://www.w3.org/2001/XMLSchema#string

Mark A Currier

http://www.w3.org/2001/XMLSchema#string

Nancy M Sawtell

http://www.w3.org/2001/XMLSchema#string

Rebecca A Gillespie

http://www.w3.org/2001/XMLSchema#string

Timothy P Cripe

http://www.w3.org/2001/XMLSchema#string

Yonatan Y Mahller

http://www.w3.org/2001/XMLSchema#string

P2860

Oncolytic herpes simplex virus vectors for cancer virotherapy

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Conditionally replicating herpes vectors for cancer therapy.

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

Role of chemotherapy in patients with soft tissue sarcomas.

P304

879-885

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2008.49

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5463470

http://www.w3.org/2001/XMLSchema#string

P698

18388918

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2860295

http://www.w3.org/2001/XMLSchema#string